TEAM vs NOW: side-by-side analysis
Cross-read of TEAM (Atlassian Corporation) versus NOW (ServiceNow Inc.): TEAM looks meaningfully undervalued at $91.6 versus a fair-value midpoint of $282, while NOW appears in our peer table. Our current rating for TEAM is Strong Buy.
Where TEAM and NOW sit on fair value
TEAM's composite fair-value range is $185–$400 (midpoint $282), versus a current price of $91.6. NOW is one of TEAM's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between TEAM and NOW is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
TEAM is classified as a pre-profit stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. NOW, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 14.7× forward P/E with a PEG of 0.98 is not the same on TEAM as it is on NOW unless they share the same growth profile, capital intensity, and moat half-life.
TEAM's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against NOW should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: TEAM looks meaningfully undervalued versus our fair-value midpoint. The full report's peer table compares TEAM and NOW directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for TEAM is bound by the kill-scenarios list in Section 2; the equivalent for NOW would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether TEAM or NOW is the better expression of the same theme.
Bottom line — TEAM or NOW?
Our rating for TEAM is Strong Buy with a 65/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes NOW. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on TEAM, including the explicit peer multiples versus NOW and the rest of the comp set, see the canonical report at /stocks/team/analysis. For NOW's standalone report, see /stocks/now/analysis.
Frequently asked questions
TEAM vs NOW: which is cheaper today?
TEAM looks meaningfully undervalued at $91.6 versus a fair-value midpoint of $282 (range $185–$400). The peer table inside the full report compares TEAM and NOW directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is TEAM a better buy than NOW?
Our current rating for TEAM is Strong Buy; we do not co-rate NOW on this page — see NOW's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is TEAM?
Atlassian Corporation is classified as a pre-profit stock, which determines our deceleration curve, terminal multiple, and probability weights. NOW's own archetype is in its own report.
What is TEAM's moat score versus NOW?
TEAM's moat score is 9/10. The full moat section covers source, durability, and threat timeline; NOW's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full TEAM report for the canonical evidence.